Evidence map›Paper›PMID 39448433›Full record

ArticleJournal of ophthalmic inflammation and infection2024

Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases.

Negin Yavari, Hashem Ghoraba, Christopher Or, Zheng Xian Thng, S Saeed Mohammadi, Irmak Karaca, Azadeh Mobasserian, Amir Akhavanrezayat, Anthony Le, Xun Lyu and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of ophthalmic inflammation and infection, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Negin YavariDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Hashem GhorabaDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Christopher OrDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Zheng Xian ThngDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
S Saeed MohammadiDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Irmak KaracaDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Azadeh MobasserianDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Amir AkhavanrezayatDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Anthony LeUniversity of Missouri Kansas City, Kansas City, MO, USA.
Xun LyuDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Anadi KhatriDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Woong Sun YooDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Dalia El FekyDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Ngoc Trong Tuong ThanDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Osama ElarabyDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Aim-On SaengsirinavinDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Xiaoyan ZhangDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Frances Andrea AnoverDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Ankur Sudhir GuptaDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Muhammad Sohail HalimDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Louis A JisonDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA.
Quan Dong NguyenDepartment of Ophthalmology, Byers Eye Institute, Stanford University, 2452 Watson Court Suite 200, 94303, Palo Alto, CA, USA. ndquan@stanford.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRepository corticotropin injection (RCI) has been suggested to exert immunomodulatory and anti-inflammatory effects in ocular inflammation. The index retrospective study aimed to evaluate the efficacy and tolerability of subcutaneous RCI in patients with active scleritis or uveitis. MAIN BODY: Medical records of patients who were diagnosed with different types of active scleritis or uveitis and received RCI for more than six months at a tertiary eye center were reviewed. Patient characteristics including age, sex, comorbidities, clinical findings, treatment details, and adverse events were recorded. A total of 17 eyes of 17 patients were included. Median age was 43 years old and 53% of patients were male. Mean treatment duration was 25.4 ± 15.5 months. Indications for RCI therapy were scleritis (7 anterior and 1 posterior) (47.8%), panuveitis (17.4%), retinal vasculitis (17.4%), chronic/recurrent anterior uveitis (13%), and posterior uveitis (4.35%). RCI was initiated at a dose of 40 to 80 units 3 times weekly. Given the adequate control of inflammation, RCI was successfully discontinued in four patients (23.5%). Prior to RCI therapy, 14 (82.3%) patients were on oral prednisone at an average of 10 mg daily (range 2.5-40 mg), and two (11.7%) patients discontinued prednisone immediately before initiating RCI due to side effects. After six months of therapy, the prednisone dose was reduced in four (23.5%) patients to an average of 3 mg daily (range 1-5 mg) and was stopped in eight (53%) patients. Concomitant immunomodulatory therapies (IMTs) included mycophenolate mofetil (23.5%) and methotrexate (23.5%), and adalimumab (23.5%). Ten patients were on IMTs prior to using RCI, and during the course of treatment, IMT was stopped in two patients and reduced in one. Side effects included insomnia (23%), hypertension (11.7%), lower extremity edema (11.7%), hyperglycemia (11.7%), weight gain (11.7%), and infection (5.8%).

conclusionRCI may be considered as a potential therapy with acceptable tolerability for patients with non-infectious scleritis or uveitis.

Indexed as

Adrenocorticotropic hormoneRepository corticotropin injectionScleritisUveitis

Identifiers

PMID39448433
PMCPMC11502637

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.